FDA OKs Intravenous Form Of UCB’s Keppra
This article was originally published in The Pink Sheet Daily
Executive Summary
UCB will launch the antiepileptic “soon,” though no specific date has been announced.
You may also be interested in...
UCB Attempts To Protect Keppra Franchise
Company asks FDA to strengthen guidelines associated with generic versions of antiepileptic drugs, as Keppra patent expiration approaches.
UCB Attempts To Protect Keppra Franchise
Company asks FDA to strengthen guidelines associated with generic versions of antiepileptic drugs, as Keppra patent expiration approaches.
GSK’s Lamictal Adds Indication As Add-On Therapy For Grand Mal Seizures
Next in the pipeline for GSK’s epilepsy franchise is an XR formulation for once-daily dosing.